IS4872A - Aðferð til að framleiða magnesíumsalt af útskiptum súlfínýl-heteróhring - Google Patents

Aðferð til að framleiða magnesíumsalt af útskiptum súlfínýl-heteróhring

Info

Publication number
IS4872A
IS4872A IS4872A IS4872A IS4872A IS 4872 A IS4872 A IS 4872A IS 4872 A IS4872 A IS 4872A IS 4872 A IS4872 A IS 4872A IS 4872 A IS4872 A IS 4872A
Authority
IS
Iceland
Prior art keywords
magnesium salt
producing magnesium
substituted sulfinyl
heterocycle
sulfinyl heterocycle
Prior art date
Application number
IS4872A
Other languages
English (en)
Other versions
IS1984B (is
Inventor
Högberg Jan-Åke
Ioannidis Panagiotis
Mattson Anders
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20402358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS4872A publication Critical patent/IS4872A/is
Publication of IS1984B publication Critical patent/IS1984B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS4872A 1996-04-26 1998-10-19 Aðferð til að framleiða magnesíumsalt af útskiptum súlfínýl-heteróhring IS1984B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9601598A SE508669C2 (sv) 1996-04-26 1996-04-26 Nytt förfarande
PCT/SE1997/000674 WO1997041114A1 (en) 1996-04-26 1997-04-22 Process for the preparation of a magnesium salt of a substituted sulphinyl heterocycle

Publications (2)

Publication Number Publication Date
IS4872A true IS4872A (is) 1998-10-19
IS1984B IS1984B (is) 2005-02-15

Family

ID=20402358

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4872A IS1984B (is) 1996-04-26 1998-10-19 Aðferð til að framleiða magnesíumsalt af útskiptum súlfínýl-heteróhring

Country Status (40)

Country Link
US (1) US6124464A (is)
EP (1) EP0897386B1 (is)
JP (1) JP4233115B2 (is)
KR (1) KR100468331B1 (is)
CN (1) CN1100776C (is)
AR (1) AR006640A1 (is)
AT (1) ATE222904T1 (is)
BR (1) BR9708829A (is)
CA (1) CA2251636C (is)
CZ (1) CZ295067B6 (is)
DE (1) DE69714987T2 (is)
DK (1) DK0897386T3 (is)
DZ (1) DZ2209A1 (is)
EE (1) EE03485B1 (is)
EG (1) EG23874A (is)
ES (1) ES2180981T3 (is)
HK (1) HK1016978A1 (is)
HR (1) HRP970210B1 (is)
HU (1) HUP9901798A3 (is)
ID (1) ID16685A (is)
IL (1) IL126716A (is)
IS (1) IS1984B (is)
MA (1) MA24143A1 (is)
MY (1) MY119011A (is)
NO (1) NO318850B1 (is)
NZ (1) NZ332154A (is)
PL (1) PL188824B1 (is)
PT (1) PT897386E (is)
RS (1) RS49718B (is)
RU (1) RU2163238C2 (is)
SA (1) SA97170759B1 (is)
SE (1) SE508669C2 (is)
SI (1) SI0897386T1 (is)
SK (1) SK282752B6 (is)
TN (1) TNSN97068A1 (is)
TR (1) TR199802156T2 (is)
TW (1) TW420676B (is)
UA (1) UA51699C2 (is)
WO (1) WO1997041114A1 (is)
ZA (1) ZA973153B (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
ATE271556T1 (de) * 1998-11-18 2004-08-15 Astrazeneca Ab Verbesserter chemischer prozess und eine pharmazeutische zubereitung
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
WO2002012225A1 (fr) * 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
ES2286408T3 (es) 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
DE10234617B4 (de) * 2002-07-29 2013-04-04 Nycomed Gmbh Neues Salz von (S)-Pantoprazol
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US20040235903A1 (en) * 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
US7507829B2 (en) * 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
ITMI20031813A1 (it) * 2003-09-23 2005-03-24 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di pantoprazolo e suoi sali.
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US20080139623A1 (en) 2006-06-12 2008-06-12 Lilach Hedvati Amorphous and crystalline forms of pantoprazole magnesium salt
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
NZ579136A (en) 2007-02-21 2012-05-25 Cipla Ltd Process for the preparation of esomeprazole magnesium dihydrate
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
CN106397399A (zh) * 2015-07-29 2017-02-15 陕西合成药业股份有限公司 一种泮托拉唑镁的精制方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
FI861772A (fi) * 1985-05-07 1986-11-08 Chemie Linz Ag Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning.
FI864138A (fi) * 1985-10-16 1987-04-17 Fisons Plc Heterocykliska blandningar.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
BR9506018A (pt) * 1994-07-08 1997-09-02 Astra Ab Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal

Also Published As

Publication number Publication date
ATE222904T1 (de) 2002-09-15
NO984903L (no) 1998-10-21
CA2251636C (en) 2001-04-10
PL329683A1 (en) 1999-04-12
DE69714987T2 (de) 2003-04-30
MA24143A1 (fr) 1997-12-31
TR199802156T2 (xx) 1999-02-22
SE9601598D0 (sv) 1996-04-26
IL126716A0 (en) 1999-08-17
IS1984B (is) 2005-02-15
PL188824B1 (pl) 2005-04-29
SA97170759B1 (ar) 2006-09-25
AU711345B2 (en) 1999-10-14
JP2000509067A (ja) 2000-07-18
CZ339898A3 (cs) 1999-03-17
KR20000065018A (ko) 2000-11-06
ZA973153B (en) 1997-10-27
EG23874A (en) 2007-11-27
TW420676B (en) 2001-02-01
ID16685A (id) 1997-10-30
HRP970210A2 (en) 1998-04-30
CN1216989A (zh) 1999-05-19
SE508669C2 (sv) 1998-10-26
HRP970210B1 (en) 2002-06-30
MY119011A (en) 2005-03-31
HUP9901798A3 (en) 2003-02-28
SE9601598L (sv) 1997-10-27
CZ295067B6 (cs) 2005-05-18
KR100468331B1 (ko) 2005-03-16
EE03485B1 (et) 2001-08-15
AU2719397A (en) 1997-11-19
EP0897386B1 (en) 2002-08-28
WO1997041114A1 (en) 1997-11-06
SI0897386T1 (en) 2002-12-31
YU44898A (sh) 1999-07-28
BR9708829A (pt) 1999-08-03
SK282752B6 (sk) 2002-12-03
HK1016978A1 (en) 1999-11-12
NO984903D0 (no) 1998-10-21
NO318850B1 (no) 2005-05-18
AR006640A1 (es) 1999-09-08
ES2180981T3 (es) 2003-02-16
US6124464A (en) 2000-09-26
TNSN97068A1 (fr) 1999-12-31
EP0897386A1 (en) 1999-02-24
RS49718B (sr) 2007-12-31
CA2251636A1 (en) 1997-11-06
JP4233115B2 (ja) 2009-03-04
NZ332154A (en) 2002-03-01
DE69714987D1 (de) 2002-10-02
HUP9901798A2 (hu) 2000-04-28
IL126716A (en) 2003-10-31
RU2163238C2 (ru) 2001-02-20
DZ2209A1 (fr) 2002-12-03
UA51699C2 (uk) 2002-12-16
DK0897386T3 (da) 2002-10-28
PT897386E (pt) 2002-12-31
EE9800363A (et) 1999-04-15
CN1100776C (zh) 2003-02-05
SK140798A3 (en) 1999-04-13

Similar Documents

Publication Publication Date Title
IS4872A (is) Aðferð til að framleiða magnesíumsalt af útskiptum súlfínýl-heteróhring
DK1273581T3 (da) Ny fremgangsmåde til fremstilling af trihydratet af magnesiumsaltet af S-omeprazol
DK1161426T3 (da) Fremgangsmåde til fremstilling af furfural
DK0885968T3 (da) Fremgangsmåde til fremstilling af vanillin
PT1219623E (pt) Novos esteres derivados de compostos fenil-ciclo-hexilicos substituidos
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1293507T3 (da) Fremgangsmåde til fremstilling af krystaller
ATE231339T1 (de) Verfahren zur bekämpfung von nachtfalterlarven
DK0911416T3 (da) Fremgangsmåde til fremstilling af protein
DE973078T1 (de) Prozesssteuersystem
DK0937068T3 (da) Fremgangsmåde til krystallisation af losartan
NO990974L (no) FremgangsmÕte for fremstilling av magnesium
DK0786450T3 (da) Fremgangsmåde til fremstilling af enantiomerer fra O-demethyltramadol
DK1225878T3 (da) RAR-gamma-selektive retinoidagonister til behandling af emfysem
DE69938126D1 (de) Stranggussverfahren
DK0973769T3 (da) Fremgangsmåde til fremstilling af eprosartan
ID22259A (id) Metoda untuk membuat lampu fluoresen
DK0842930T3 (da) Fremgangsmåde til syntese af benzothiophener
NO992797D0 (no) FremgangsmÕte for fremstilling av et eter-karboksylatsalt
DK0970073T3 (da) Fremgangsmåde til fremstilling af eprosartan
AR025435A1 (es) Metodo para sintetizar mezclas de oligosacaridos derivados de (fosfato-ribosa-ribitol)n o de (ribosa-ribitol-fosfato)n y disacaridos intermedios de los mismos
DK1023279T3 (da) Forbindelser og fremgangsmåde til fremstilling af substituerede 4-phenyl-4-cyanocyclohexansyrer
NO20005148D0 (no) FremgangsmÕte for Õ fremstille 4-substituerte-1H-indol-3- glyoksamider
IS5602A (is) Aðferð til að framleiða ál
DK0923565T3 (da) Fremgangsmåde til fremstilling af paclitaxel